Press Releases Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
2.31 ^USD	+5.00%		-1.70%	-0.43%

May. 09	Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mersana Therapeutics to Present at Upcoming Investor Conferences	May. 22	AQ
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results	May. 09	AQ
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 03	AQ
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024	May. 02	AQ
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 04	AQ
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	Feb. 28	AQ
Mersana Therapeutics to Present at Upcoming Investor Conferences	Feb. 27	AQ
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024	Feb. 21	AQ
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference	Feb. 01	AQ
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 05	AQ
Mersana Therapeutics : Termination of Material Agreement - Form 8-K	Dec. 21	PU
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 01	AQ
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results	Nov. 07	AQ
Dynamic Innovators: Nano-Cap Stock Watchlist (SING, LILM, OMQS, MRSN)	Nov. 01	AQ
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023	23-10-31	AQ
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056	23-10-31	AQ
Mersana Therapeutics Announces Changes in Leadership	23-09-06	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN	23-08-18	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN	23-08-10	PR
Mersana Therapeutics Announces Second Quarter 2023 Financial Results	23-08-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Press Releases

Filters